BCC016: Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma

Neuroscience

1. Medulloblastoma 100%
2. Eflornithine 100%
3. Polyamine 33%
4. Anabolism 16%
5. Ornithine Decarboxylase 16%
6. Hedgehog Signaling Pathway 16%
7. Intracranial Tumor 16%
8. Pediatrics 16%
9. Biosynthesis 16%